At Foghorn, we pledge to partner with patients as we work to discover and develop new, effective therapies for a wide spectrum of diseases, including many types of cancer. Every member of our team is committed to making a difference in the lives of others.
Clinical trials are studies that are conducted to evaluate the safety and effectiveness of a new therapy. These studies are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Evaluating safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of FHD-609 in patients with advanced Synovial Sarcoma
Status: COMING SOON
Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Evaluating safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of FHD-286 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) or relapsed or refractory Myelodysplastic Syndromes (MDS)
Status: OPEN AND RECRUITING
POLICY ON EXPANDED ACCESS (EA) TO INVESTIGATIONAL DRUGS
Foghorn understands that there are some cases when a patient is unable to participate in a clinical trial, and other treatment options have been exhausted. In those cases, the patient’s physician may choose to request access to an investigational drug outside of a clinical trial via what is termed Expanded Access in the United States.
Currently, participation in clinical trials is the only way for patients to gain access to Foghorn’s investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we will review and update our policy on Expanded Access.